This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Selvakumaran, M. Articles by Hamilton, T. C. Search for Related Content PubMed PubMed Citation Articles by Selvakumaran, M. Articles by Hamilton, T. C.

Ovarian Epithelial Cell Lineage-specific Gene Expression Using the Promoter of a Retrovirus-like Element¹

Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111

We have isolated 462 bp of sequence termed ovarian-specific promoter 1 (OSP-1) that is part of a retrovirus-like element specifically expressed in the rat ovary. We have evaluated the ability of OSP-1 to activate gene expression in normal and neoplastic cell lines derived from the ovaries of rats and women. We have found that there was marked specificity in the ability of OSP-1 to drive reporter gene expression in an ovarian epithelial cell lineage manner. The expression of herpes simplex virus thymidine kinase (HSV-TK) under OSP-1 control was sufficiently ovarian cancer cell line specific to render ganciclovir 50-fold more toxic in the A2780 human ovarian cancer cell line compared with clones of the HCT-116 and HT-29 colon cancer cell lines. Furthermore, ganciclovir had marked antitumor efficacy in vivo in severe combined immunodeficient mice bearing A2780^OSP-1-HSV-TK as a s.c. xenograft. We suggest that these data support the use of OSP-1 as a tool to provide specificity to the gene therapy of ovarian cancer and to drive ovarian-specific oncogene expression for the creation of transgenic mouse models of ovarian cancer.

This article has been cited by other articles:

				K. Garson, E. Macdonald, M. Dube, R. Bao, T. C. Hamilton, and B. C. Vanderhyden Generation of Tumors in Transgenic Mice Expressing the SV40 T Antigen Under the Control of Ovarian-Specific Promoter 1 Reproductive Sciences, May 1, 2003; 10(4): 244 - 250. [Abstract] [PDF]

				R. Bao, D. C. Connolly, M. Murphy, J. Green, J. K. Weinstein, D. A. Pisarcik, and T. C. Hamilton Activation of Cancer-Specific Gene Expression by the Survivin Promoter J Natl Cancer Inst, April 3, 2002; 94(7): 522 - 528. [Abstract] [Full Text] [PDF]

				M. E. Murphy The Battle between Tumor Suppressors: Is Gene Therapy Using p16INK4a More Efficacious Than p53 for Treatment of Ovarian Carcinoma? : Commentary re: S. C. Modesitt et al., In Vitro and In Vivo Adenovirus-mediated p53 and p16 Tumor Suppressor Therapy in Ovarian Cancer. Clin. Cancer Res., 7: 1765-1772, 2001. Clin. Cancer Res., June 1, 2001; 7(6): 1487 - 1489. [Full Text] [PDF]